Salipro Biotech and DyNAbind Announce Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins
The collaboration combines the benefits of Salipro Biotech’s proprietary platform technology for membrane proteins with DyNAbind’s proprietary DNA-Encoded Library (DEL) technology to accelerate the development of novel drugs for challenging targets.
- The collaboration combines the benefits of Salipro Biotech’s proprietary platform technology for membrane proteins with DyNAbind’s proprietary DNA-Encoded Library (DEL) technology to accelerate the development of novel drugs for challenging targets.
- Jens Frauenfeld, CEO of Salipro Biotech, said, "We are excited about this milestone in our collaboration with DyNAbind.
- Our Salipro® platform technology for membrane proteins combined with DyNAbind's Dynamic Library technology has opened up new avenues for drug discovery against challenging targets.
- This collaboration represents a significant development in the field of DEL and membrane proteins, showcasing the potential for cutting-edge technologies to transform drug discovery.